Gesine Meyer-Rath

Research Assistant Professor, International Health

Free University of Berlin, PhD
Free University of Berlin and Humboldt University, MD

  • Office: Johannesburg, South Africa
  • Phone: 617-414-1260
  • Email: gesine@bu.edu

Biography

Gesine Meyer-Rath, MD, PhD, is a physician, health economist, and infectious disease modeler with seven years’ experience in economic evaluations of health care interventions. She is Research Assistant Professor of International Health at the Center for Global Health & Development working on the economics of HIV and antiretroviral treatment (ART) in resource-limited settings. Her focus lies on modeling methods for economic evaluation, including infectious disease modeling and decision analysis, and translating research into recommendations for public policy. Before joining the CGHD, she worked in the Pediatrics Department of Charité University Hospital Berlin and with the World Health Organization, where she helped with the generalized cost-effectiveness analysis of the ChoICE team and, in 2003, the calculation of the cost of WHO’s “3 by 5” program. From 2006 to 2008, she was a research fellow at the Health Policy Unit of the London School of Hygiene and Tropical Medicine (UK) and a visiting researcher at the Reproductive Health and HIV Research Unit of the University of the Witwatersrand in Johannesburg, South Africa. During this time, she developed mathematical models for the analysis of the cost, outcomes, and economic impact of ART provision in mining companies in South Africa and, for UNICEF, of global resource needs for the care of orphans and vulnerable children. She has worked in and trained health economists from four sub-Saharan African countries and has been resident in South Africa since 2006. Dr. Meyer-Rath currently works on modeling the budgetary requirements for national ART and PMTCT programs and on analyzing the cost and outcomes of pediatric ART provision. She holds an MD/PhD from Humboldt University and Free University, Berlin, Germany, and is pursuing a PhD in Health Economics at the London School of Hygiene and Tropical Medicine.

Projects

Publications

Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models

Jeffrey W Eaton, Nicolas A Menzies, John Stover, Valentina Cambiano, Leonid Chindelevitch, Anne Cori, Jan A C Hontelez, Salal Humair, Cliff C Kerr, Daniel J Klein, Sharmistha Mishra, Kate M Mitchell, Brooke E Nichols, Peter Vickerman, Roel Bakker, Till Bärnighausen, Anna Bershteyn, David E Bloom, Marie-Claude Boily, Stewart T Chang, Ted Cohen, Peter J Dodd, Christophe Fraser, Chaitra Gopalappa, Jens Lundgren, Natasha K Martin, Evelinn Mikkelsen, Elisa Mountain, Quang D Pham, Michael Pickles, Andrew Phillips, Lucy Platt, Carel Pretorius, Holly J Prudden, Joshua A Salomon, David A M C van de Vijver, Sake J de Vlas, Bradley G Wagner, Richard G White, David P Wilson, Lei Zhang, John Blandford, Gesine Meyer-Rath, Michelle Remme, Paul Revill, Nalinee Sangrujee, Fern Terris-Prestholt, Meg Doherty, Nathan Shaffer, Philippa J Easterbrook, Gottfried Hirnschall, Timothy B Hallett

The Lancet Global Health. 2014 Jan; 2(1).

Cost-effectiveness of tenofovir gel in urban South Africa: model projections of HIV impact and threshold product prices

Fern Terris-Prestholt, Anna M. Foss, Andrew P. Cox, Lori Heise, Gesine Meyer-Rath, Sinead Delany-Moretlwe, Thomas Mertenskoetter, Helen Rees, Peter Vickerman, Charlotte H. Watts

BMC Infectious Diseases. 2014 Jan; 14(14).

Retention in Care and Outpatient Costs for Children Receiving Antiretroviral Therapy in Zambia: A Retrospective Cohort Analysis

Callie A. Scott, Hari Iyer, Deophine Lembela Bwalya, Kelly McCoy, Gesine Meyer-Rath, Crispin Moyo, Carolyn Bolton-Moore, Bruce Larson, and Sydney Rosen

PLoS ONE. 2013 Jun; 8(6).

Diagnosing Xpert MTB/RIF-negative TB: Impact and cost of alternative algorithms for South Africa

K Schnippel, G Meyer-Rath, L Long, W S Stevens, I Sanne, S Rosen

The South African Medical Journal. 2013 Feb; 103(2).

Cost and Outcomes of Paediatric Antiretroviral Treatment in South Africa

Gesine Meyer-Rath, Alana Brennan, Lawrence Long, Buyiswa Ndibongo, Karl Technau, Harry Moultrie, Lee Fairlie, Ashraf Coovadia and Sydney Rosen

AIDS 2012. 2013 Jan; 14(27):243-250.

Rates and Cost of Hospitalization Before and After Initiation of Antiretroviral Therapy in Urban and Rural Settings in South Africa

Gesine Meyer-Rath, Alana T. Brennan, Matthew P. Fox, Tebogo Modisenyane, Nkeko Tshabangu, Lerato Mohapi, Sydney Rosen, and Neil Martinson

JAIDS. 2013 Jan; 62(3):322-328.

Cost and Resource Use of Patients on Antiretroviral Therapy in the Urban and Semiurban Public Sectors of South Africa

Gesine Meyer-Rath, MD, Alec Miners, PhD, Andreia C. Santos, PhD, Ebrahim Variava, MD, and Willem Daniel Francois Venter, MD

JAIDS. 2012 Nov; 61(3):25-32.

Scaling up Xpert MTB⁄RIF technology: the costs of laboratory vs. clinic-based roll-out in South Africa

Kathryn Schnippel, Gesine Meyer-Rath, Lawrence Long, William MacLeod, Ian Sanne, Wendy S. Stevens and Sydney Rosen

Tropical Medicine and International Health. 2012 Jun; 00(00):1-10.

The Impact and Cost of Scaling up GeneXpert MTB/RIF in South Africa

Gesine Meyer-Rath, Kathryn Schnippel, Lawrence Long, William MacLeod, Ian Sanne, Wendy Stevens, Sagie Pillay, Yogan Pillay, Sydney Rosen

PLoS ONE. 2012 May; 7(5):1-11.

The Incremental Cost Of Introducing Xpert® MTB/RIF into the South African National Tuberculosis Programme

Meyer-Rath G., Bistline K., Long L., MacLeod W., Sanne I., Stevens W., Rosen S.

Johannesburg, South Africa; Boston, MA: Health Economics and Epidemiology Research Office, Wits Health Consortium, University of the Witwatersrand (HE2RO); 2011 Jul.

Total Cost and Potential Cost Savings of the National Antiretroviral Treatment (ART) Programme in South Africa 2010 to 2017. Abstract 16112

Meyer-Rath G., Brennan A., Long L., Rosen S., Pillay Y., Johnson L., Mbengashe T., Dlamini N., Fox M.P.

18th International AIDS Conference; 2010 Jul 18; Vienna.

Survival in Care and CD4 Cell Count Gain on First-line ART Depend on Prior CD4 Cell Count and Time on Treatment: Evidence From a Large South African Cohort. Abstract Z-184

Meyer-Rath G., Brennan A., Long L., Rosen S.B., Fox M.P.

17th Conference on Retroviruses and Opportunistic Infections (CROI); 2010 Feb 1; San Francisco.

Good Treatment Outcomes among Foreigners Receiving Antiretroviral Therapy in Johannesburg, South Africa

McCarthy K., Chersich M. F., Vearey J., Meyer-Rath G., Jaffer A., Simpwalo S., Venter W. D.

Int J STD AIDS. 2009 Dec; 20(12):858-62.

The Cost-Effectiveness of HIV Control: Getting the Priorities Right

Meyer-Rath G.

South Afr J HIV Med. 2007 Jun; 8(2):15-16.

User Fees, Transport Costs, and the Ethics of Exemption: How Free is Free ART?

Meyer-Rath G., Richter M.

South Afr J HIV Med. 2007 Jun; 8(2):52-56.